In vitro and in vivo effect of 5-FC combined gene therapy with TNF-α and CD suicide gene on human laryngeal carcinoma cell line Hep-2
- PMID: 23593411
- PMCID: PMC3623900
- DOI: 10.1371/journal.pone.0061136
In vitro and in vivo effect of 5-FC combined gene therapy with TNF-α and CD suicide gene on human laryngeal carcinoma cell line Hep-2
Abstract
This study was aimed to investigate the effect of combined cancer gene therapy with exogenous tumor necrosis factor-alpha (TNF-α) and cytosine deaminase (CD) suicide gene on laryngeal carcinoma cell line Hep-2 in vitro and in vivo. Transfection of the recombinant eukaryotic vectors of pcDNA3.1 (+) containing TNF-α and/or CD into Hep-2 cells resulted in expression of TNF-α and/or CD gene in vitro. The significant increase in apoptotic Hep-2 cells and decrease of Hep-2 cell proliferation were observed using 5-FC treatment combined with TNF-a expression by CD/5-FC suicide system. Moreover, bystander effect was also observed in the TNF-α and CD gene co-expression group. Laryngeal squamous cell carcinoma (LSCC) mice model was established by using BALB/c mice which different transfected Hep-2 cells with pcDNA3.1 (+) containing TNF-α and/or CD were applied subcutaneously. So these mice are divided into four groups, namely, (1)Hep-2/TIC group; (2)Hep-2/CD group; (3)Hep-2/TNF-α group; (4)Hep-2/0 group. At day 29 after cell inoculation, volume of grafted tumor had significant difference between each two of them (P<0.05). These results showed that the products of combined CD and TNF-α genes inhibited the growth of transplanted LSCC in mice model. So by our observed parameters and many others results, we hypothesized that 5-FC combined gene therapy with TNF-αand CD suicide gene should be an effective treatment on Laryngeal carcinoma.
Conflict of interest statement
Figures









Similar articles
-
Treatment of human tumor cells by combine gene therapy harnessing plasmids expressing human tumor necrosis factor alpha and bacterial cytosine deaminase suicide gene.Neoplasma. 2006;53(6):478-84. Neoplasma. 2006. PMID: 17167715
-
Antitumor efficacy of VP22-CD/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model.Exp Eye Res. 2018 Jul;172:144-151. doi: 10.1016/j.exer.2018.04.009. Epub 2018 Apr 13. Exp Eye Res. 2018. PMID: 29660328
-
[In vitro experimental study of killing Hep-2 cells of laryngeal cancer with suicide fusion gene CDglyTK].Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2007 Jun;21(12):555-8. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2007. PMID: 17802830 Chinese.
-
Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study.Med Sci Monit. 2009 Jan;15(1):BR13-20. Med Sci Monit. 2009. PMID: 19114960
-
Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.Cancer Gene Ther. 2012 Sep;19(9):593-600. doi: 10.1038/cgt.2012.36. Epub 2012 Jun 29. Cancer Gene Ther. 2012. PMID: 22744209 Review.
Cited by
-
New biomarker: the gene HLA-DRA associated with low-grade glioma prognosis.Chin Neurosurg J. 2022 May 19;8(1):12. doi: 10.1186/s41016-022-00278-0. Chin Neurosurg J. 2022. PMID: 35585639 Free PMC article.
-
RGD-Targeted Ultrasound Contrast Agent for Longitudinal Assessment of Hep-2 Tumor Angiogenesis In Vivo.PLoS One. 2016 Feb 10;11(2):e0149075. doi: 10.1371/journal.pone.0149075. eCollection 2016. PLoS One. 2016. PMID: 26862757 Free PMC article.
-
Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy.J Cancer Res Ther (Manch). 2014;2(1):22-33. doi: 10.14312/2052-4994.2014-4. J Cancer Res Ther (Manch). 2014. PMID: 24860662 Free PMC article.
-
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges.ACS Nano. 2024 Sep 10;18(36):24650-24681. doi: 10.1021/acsnano.3c10797. Epub 2024 Aug 26. ACS Nano. 2024. PMID: 39185745 Free PMC article. Review.
-
Engineering Circulating Tumor Cells as Novel Cancer Theranostics.Theranostics. 2020 Jun 29;10(17):7925-7937. doi: 10.7150/thno.44259. eCollection 2020. Theranostics. 2020. PMID: 32685030 Free PMC article.
References
-
- Uslu C, Taysi S, Akcay F, Sutbeyaz MY, Bakan N (2003) Serum Free and Bound Siali Acid and Alpha-l-Acid Glycoprotein in Patients with Laryngeal Cancer. Annals of Clinical & Laboratory Science 33: 156–159. - PubMed
-
- Tamarit Conejeros JM, Carrasco Llatas M, Estellés Ferriol E, Fernández Martínez S, Baviera Granell N, et al. (2007) Supraglottic and glottic carcinomas. Study of the incidence in the last 31 years. Acta Otorrinolaringol Esp 58(10): 449–453. - PubMed
-
- Shang C (2003) Advances in Molecular Cytogenetics of Laryngeal Carcinoma on Foreign Medical Science: Subvolume of Internal Medicine. Subvolume of Genetics 26 (6): 360–363.
-
- Hawkins NV (1975) The treatment of glottic carcinoma:an analysis of 800 cases. Laryngoscope 85: 1485–1493. - PubMed
-
- Shah JP, Tollefsen HR (1974) Epidermoid carcinoma of the supraglottic larynx.Role of neck dissection in initial surgical treatment. Am J Surg. 128: 494–499. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical